Literature DB >> 2883980

Plasma levels and pharmacokinetics of single and multiple dose of tetrazepam in healthy volunteers.

H Bun, F Philip, Y Berger, J Necciari, N R Al-Mallah, A Serradimign, J P Cano.   

Abstract

The pharmacokinetics of tetrazepam (Myolastan, Musaril), were studied in 12 healthy volunteers. Tetrazepam was given orally as a single dose of 50 mg and repeated administration for 5 consecutive days of 50 mg at 12-h intervals, in tablet form. Tetrazepam was measured in plasma using a selective and sensitive GLC method. Tetrazepam is rapidly absorbed after oral administration with a peak plasma level of 0.49 +/- 0.10 mg/l at 0.94 +/- 0.47 h. The drug is widely distributed in the organism with an apparent volume of distribution of 6.7 +/- 2.1 l/kg. Tetrazepam is eliminated with a half-life of 22 +/- 4 h and can be classified as a benzodiazepine with medium half-life value. This medium half-life is the result of the high hepatic clearance of the drug in spite of its large distribution volume. Since in this study 6 male and 6 female volunteers were studied it was possible to compare the pharmacokinetic profile in the two groups. No significant differences were observed. No differences were observed between the pharmacokinetic values after a single dose or after repeated administration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2883980

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  2 in total

1.  Medicolegal aspects of tetrazepam metabolism.

Authors:  Marion Pavlic; Kathrin Libiseller; Petra Grubwieser; Heinrich Schubert; Walter Rabl
Journal:  Int J Legal Med       Date:  2006-10-05       Impact factor: 2.791

2.  Recovery cycles of posterior root-muscle reflexes evoked by transcutaneous spinal cord stimulation and of the H reflex in individuals with intact and injured spinal cord.

Authors:  Ursula S Hofstoetter; Brigitta Freundl; Heinrich Binder; Karen Minassian
Journal:  PLoS One       Date:  2019-12-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.